Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Context-dependent antagonism between Akt inhibitors and topoisomerase poisons.

Gálvez-Peralta M, Flatten KS, Loegering DA, Peterson KL, Schneider PA, Erlichman C, Kaufmann SH.

Mol Pharmacol. 2014 May;85(5):723-34. doi: 10.1124/mol.113.088674. Epub 2014 Feb 25.

2.

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.

Ding H, McDonald JS, Yun S, Schneider PA, Peterson KL, Flatten KS, Loegering DA, Oberg AL, Riska SM, Huang S, Sinicrope FA, Adjei AA, Karp JE, Meng XW, Kaufmann SH.

Haematologica. 2014 Jan;99(1):60-9. doi: 10.3324/haematol.2013.087734. Epub 2013 Aug 30.

3.

PKC-ε pseudosubstrate and catalytic activity are necessary for membrane delivery during IgG-mediated phagocytosis.

Wood TR, Chow RY, Hanes CM, Zhang X, Kashiwagi K, Shirai Y, Trebak M, Loegering DJ, Saito N, Lennartz MR.

J Leukoc Biol. 2013 Jul;94(1):109-22. doi: 10.1189/jlb.1212634. Epub 2013 May 13.

4.

Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm.

Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH.

Cell Death Differ. 2013 Jan;20(1):64-76. doi: 10.1038/cdd.2012.93. Epub 2012 Aug 3.

5.

Ultrasound biomicroscopy for longitudinal studies of carotid plaque development in mice: validation with histological endpoints.

Harmon EY, Fronhofer V, Keller RS, Feustel PJ, Brosnan MJ, von der Thüsen JH, Loegering DJ, Lennartz MR.

PLoS One. 2012;7(1):e29944. doi: 10.1371/journal.pone.0029944. Epub 2012 Jan 5.

6.

Protein kinase C and toll-like receptor signaling.

Loegering DJ, Lennartz MR.

Enzyme Res. 2011;2011:537821. doi: 10.4061/2011/537821. Epub 2011 Aug 23.

7.

Ligation of macrophage Fcγ receptors recapitulates the gene expression pattern of vulnerable human carotid plaques.

Lennartz MR, Aggarwal A, Michaud TM, Feustel PJ, Jones DM, Brosnan MJ, Keller RS, Loegering DJ, Kreienberg PB.

PLoS One. 2011;6(7):e21803. doi: 10.1371/journal.pone.0021803. Epub 2011 Jul 21.

8.

Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM.

Haematologica. 2011 Nov;96(11):1619-26. doi: 10.3324/haematol.2011.049551. Epub 2011 Jul 26.

9.

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.

Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH.

Blood. 2011 Nov 3;118(18):4882-9. doi: 10.1182/blood-2011-02-334904. Epub 2011 Jul 1.

10.
11.

Long-term calibration considerations during subcutaneous microdialysis sampling in mobile rats.

Mou X, Lennartz MR, Loegering DJ, Stenken JA.

Biomaterials. 2010 Jun;31(16):4530-9. doi: 10.1016/j.biomaterials.2010.02.016. Epub 2010 Mar 11.

12.

Detection of in vivo matrix metalloproteinase activity using microdialysis sampling and liquid chromatography/mass spectrometry.

Wang Y, Zagorevski DV, Lennartz MR, Loegering DJ, Stenken JA.

Anal Chem. 2009 Dec 15;81(24):9961-71. doi: 10.1021/ac901703g.

13.

Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.

Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Gomez TS, Peterson KL, Trushin SA, Hess AD, Smith BD, Karp JE, Billadeau DD, Kaufmann SH.

J Biol Chem. 2010 Jan 8;285(2):888-902. doi: 10.1074/jbc.M109.057638. Epub 2009 Nov 3.

14.

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.

Wahner Hendrickson AE, Haluska P, Schneider PA, Loegering DA, Peterson KL, Attar R, Smith BD, Erlichman C, Gottardis M, Karp JE, Carboni JM, Kaufmann SH.

Cancer Res. 2009 Oct 1;69(19):7635-43. doi: 10.1158/0008-5472.CAN-09-0511. Epub 2009 Sep 29.

15.

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH.

Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24.

16.

Adaptation of Francisella tularensis to the mammalian environment is governed by cues which can be mimicked in vitro.

Hazlett KR, Caldon SD, McArthur DG, Cirillo KA, Kirimanjeswara GS, Magguilli ML, Malik M, Shah A, Broderick S, Golovliov I, Metzger DW, Rajan K, Sellati TJ, Loegering DJ.

Infect Immun. 2008 Oct;76(10):4479-88. doi: 10.1128/IAI.00610-08. Epub 2008 Jul 21.

17.

Multiplexed cytokine detection of interstitial fluid collected from polymeric hollow tube implants--a feasibility study.

Wang X, Lennartz MR, Loegering DJ, Stenken JA.

Cytokine. 2008 Jul;43(1):15-9. doi: 10.1016/j.cyto.2008.04.009. Epub 2008 Jun 2.

18.

Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.

Gálvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM, Kaufmann SH.

Mol Pharmacol. 2008 Sep;74(3):724-35. doi: 10.1124/mol.108.047787. Epub 2008 May 28.

19.

Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I.

Hackbarth JS, Galvez-Peralta M, Dai NT, Loegering DA, Peterson KL, Meng XW, Karnitz LM, Kaufmann SH.

J Biol Chem. 2008 Jun 13;283(24):16711-22. doi: 10.1074/jbc.M802246200. Epub 2008 Apr 11.

20.

Apoptosis-associated caspase activation assays.

Kaufmann SH, Lee SH, Meng XW, Loegering DA, Kottke TJ, Henzing AJ, Ruchaud S, Samejima K, Earnshaw WC.

Methods. 2008 Mar;44(3):262-72. doi: 10.1016/j.ymeth.2007.11.005. Review.

PMID:
18314058
21.

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH.

J Biol Chem. 2007 Oct 12;282(41):29831-46. Epub 2007 Aug 13.

22.

Interleukin-6 collection through long-term implanted microdialysis sampling probes in rat subcutaneous space.

Wang X, Lennartz MR, Loegering DJ, Stenken JA.

Anal Chem. 2007 Mar 1;79(5):1816-24. Epub 2007 Jan 31.

PMID:
17263512
23.

Major basic protein homolog (MBP2): a specific human eosinophil marker.

Plager DA, Loegering DA, Checkel JL, Tang J, Kephart GM, Caffes PL, Adolphson CR, Ohnuki LE, Gleich GJ.

J Immunol. 2006 Nov 15;177(10):7340-5.

24.

Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitro.

Loegering DJ, Drake JR, Banas JA, McNealy TL, Mc Arthur DG, Webster LM, Lennartz MR.

Microb Pathog. 2006 Dec;41(6):218-25. Epub 2006 Sep 25.

25.

Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.

Mesa RA, Tefferi A, Lasho TS, Loegering D, McClure RF, Powell HL, Dai NT, Steensma DP, Kaufmann SH.

Leukemia. 2006 Oct;20(10):1800-8. Epub 2006 Jul 27.

PMID:
16871275
26.

In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.

Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, Frennesson DB, Kalli KR, Conover CA, Attar RM, Kaufmann SH, Gottardis M, Erlichman C.

Cancer Res. 2006 Jan 1;66(1):362-71.

27.

Role of PKC isoforms in the Fc(gamma)R-mediated inhibition of LPS-stimulated IL-12 secretion by macrophages.

Fronhofer V, Lennartz MR, Loegering DJ.

J Leukoc Biol. 2006 Feb;79(2):408-15. Epub 2005 Dec 5.

PMID:
16330529
28.

Targeting of protein kinase C-epsilon during Fcgamma receptor-dependent phagocytosis requires the epsilonC1B domain and phospholipase C-gamma1.

Cheeseman KL, Ueyama T, Michaud TM, Kashiwagi K, Wang D, Flax LA, Shirai Y, Loegering DJ, Saito N, Lennartz MR.

Mol Biol Cell. 2006 Feb;17(2):799-813. Epub 2005 Nov 30.

29.

Evaluation of the role of caspase-6 in anticancer drug-induced apoptosis.

Loegering DA, Ruchaud S, Earnshaw WC, Kaufmann SH.

Cell Death Differ. 2006 Feb;13(2):346-7. No abstract available.

30.

Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.

Chandra J, Tracy J, Loegering D, Flatten K, Verstovsek S, Beran M, Gorre M, Estrov Z, Donato N, Talpaz M, Sawyers C, Bhalla K, Karp J, Sausville E, Kaufmann SH.

Blood. 2006 Mar 15;107(6):2501-6. Epub 2005 Nov 15.

31.

Differential extraction of eosinophil granule proteins.

Ohnuki LE, Wagner LA, Georgelas A, Loegering DA, Checkel JL, Plager DA, Gleich GJ.

J Immunol Methods. 2005 Dec 20;307(1-2):54-61. Epub 2005 Oct 17.

PMID:
16257006
32.

Multiplexed cytokine detection in microliter microdialysis samples obtained from activated cultured macrophages.

Ao X, Wang X, Lennartz MR, Loegering DJ, Stenken JA.

J Pharm Biomed Anal. 2006 Mar 3;40(4):915-21. Epub 2005 Oct 19.

PMID:
16242281
33.

Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.

Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C.

Clin Cancer Res. 2005 Sep 15;11(18):6641-9.

34.

Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.

Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, Lieberman HB, Chen J, Cliby WA, Kaufmann SH.

Mol Pharmacol. 2005 Dec;68(6):1636-44. Epub 2005 Aug 26.

35.

In vivo microdialysis sampling of cytokines produced in mice given bacterial lipopolysaccharide.

Ao X, Rotundo RF, Loegering DJ, Stenken JA.

J Microbiol Methods. 2005 Sep;62(3):327-36.

PMID:
15936098
36.

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.

Mesa RA, Loegering D, Powell HL, Flatten K, Arlander SJ, Dai NT, Heldebrant MP, Vroman BT, Smith BD, Karp JE, Eyck CJ, Erlichman C, Kaufmann SH, Karnitz LM.

Blood. 2005 Jul 1;106(1):318-27. Epub 2005 Mar 22.

37.

The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.

Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH.

J Biol Chem. 2005 Apr 8;280(14):14349-55. Epub 2005 Feb 7.

38.

Proteomic analysis of mantle-cell lymphoma by protein microarray.

Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE.

Blood. 2005 May 1;105(9):3722-30. Epub 2005 Jan 13.

39.

Components of the cell death machine and drug sensitivity of the National Cancer Institute Cell Line Panel.

Svingen PA, Loegering D, Rodriquez J, Meng XW, Mesner PW Jr, Holbeck S, Monks A, Krajewski S, Scudiero DA, Sausville EA, Reed JC, Lazebnik YA, Kaufmann SH.

Clin Cancer Res. 2004 Oct 15;10(20):6807-20.

41.

Rad9 protects cells from topoisomerase poison-induced cell death.

Loegering D, Arlander SJ, Hackbarth J, Vroman BT, Roos-Mattjus P, Hopkins KM, Lieberman HB, Karnitz LM, Kaufmann SH.

J Biol Chem. 2004 Apr 30;279(18):18641-7. Epub 2004 Feb 25.

42.

Caspase-7 gene disruption reveals an involvement of the enzyme during the early stages of apoptosis.

Korfali N, Ruchaud S, Loegering D, Bernard D, Dingwall C, Kaufmann SH, Earnshaw WC.

J Biol Chem. 2004 Jan 9;279(2):1030-9. Epub 2003 Oct 28.

43.

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro.

Meng XW, Chandra J, Loegering D, Van Becelaere K, Kottke TJ, Gore SD, Karp JE, Sebolt-Leopold J, Kaufmann SH.

J Biol Chem. 2003 Nov 21;278(47):47326-39. Epub 2003 Sep 8.

44.

Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells.

Chandra J, Hackbarth J, Le S, Loegering D, Bone N, Bruzek LM, Narayanan VL, Adjei AA, Kay NE, Tefferi A, Karp JE, Sausville EA, Kaufmann SH.

Blood. 2003 Dec 15;102(13):4512-9. Epub 2003 Aug 14.

45.

A modular on-line three-dimensional liquid chromatography-tandem mass spectrometry approach to characterization of organelle proteomes.

Johnson KL, Loegering DA, Gleich GJ, Naylor S.

Biomed Chromatogr. 2003 Mar-Apr;17(2-3):106-12.

PMID:
12717798
47.

A role for PKC-epsilon in Fc gammaR-mediated phagocytosis by RAW 264.7 cells.

Larsen EC, Ueyama T, Brannock PM, Shirai Y, Saito N, Larsson C, Loegering D, Weber PB, Lennartz MR.

J Cell Biol. 2002 Dec 23;159(6):939-44. Epub 2002 Dec 23.

48.

Peptide-based analysis of amino acid sequences important to the biological activity of eosinophil granule major basic protein.

Thomas LL, Kubo H, Loegering DJ, Spillard K, Weaver AJ, McCormick DJ, Weiler C, Gleich GJ.

Immunol Lett. 2001 Oct 1;78(3):175-81.

PMID:
11578692
49.

Crystal structure of the eosinophil major basic protein at 1.8 A. An atypical lectin with a paradigm shift in specificity.

Swaminathan GJ, Weaver AJ, Loegering DA, Checkel JL, Leonidas DD, Gleich GJ, Acharya KR.

J Biol Chem. 2001 Jul 13;276(28):26197-203. Epub 2001 Apr 23.

50.

Fcgamma-receptor signaling augments the LPS-stimulated increase in serum tumor necrosis factor-alpha levels.

Refici ML, Metzger DW, Arulanandam BP, Lennartz MR, Loegering DJ.

Am J Physiol Regul Integr Comp Physiol. 2001 Apr;280(4):R1037-44.

Supplemental Content

Loading ...
Support Center